Drug intelligence / Profile preview

89Zr-βS-hRS7 + 177Lu-βS-hRS7

Development stage
Preclinical
Lead developer
Peking University Cancer Hospital & Institute
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

89Zr-βS-hRS7 + 177Lu-βS-hRS7 is a site-specifically glycan-conjugated theranostic pair targeting Trophoblast cell-surface antigen 2 (TROP2). Developed by researchers at Peking University Cancer Hospital & Institute, the theranostic pair consists of the humanized anti-TROP2 monoclonal antibody hRS7 site-specifically conjugated with DFO/DOTA chelators via β-galactosidase and galactosyltransferase, followed by radiolabeling with zirconium-89 (89Zr) for PET/CT imaging or lutetium-177 (177Lu) for targeted radionuclide therapy. In preclinical models of TROP2-positive triple-negative breast cancer (TNBC), the site-specific theranostic pair demonstrated superior TROP2 affinity, tumor targeting, and retention compared to conventional randomly conjugated probes, resulting in improved imaging contrast and enhanced therapeutic efficacy.

Other names
89Zr-betaS-hRS7 + 177Lu-betaS-hRS789Zr-betaS-hRS7 and 177Lu-betaS-hRS789Zr-betaS-hRS7/177Lu-betaS-hRS789Zr-βS-hRS7 + 177Lu-βS-hRS789Zr-βS-hRS7 and 177Lu-βS-hRS789Zr-βS-hRS7/177Lu-βS-hRS7
02

Identity

Drug type
Antibody-Based Therapeutics
Modality
Monoclonal AntibodiesAntibody-Radionuclide ConjugatesBeta-minus EmittersPositron Emitters
03

Pharmacology

04

Development

IndicationHighest phaseStatus
triple-negative breast cancer (TNBC) / hormone-receptor-negative, HER2-negative breast cancer (HR-/HER2-)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Peking University Cancer Hospital & InstituteLead developer
07

Competitive landscape

Drugs on the same target
62
Drugs in the lead indication
722

Lead indication: triple-negative breast cancer (TNBC) / hormone-receptor-negative, HER2-negative breast cancer (HR-/HER2-)

Most advanced in the lead indication

  1. datopotamab deruxtecanApproved
  2. sacituzumab govitecanApproved
  3. pembrolizumabApproved
  4. anastrozolePhase 4
  5. bevacizumabPhase 4

Beyond the preview

Go deeper on 89Zr-βS-hRS7 + 177Lu-βS-hRS7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 89Zr-βS-hRS7 + 177Lu-βS-hRS7.

Work on 89Zr-βS-hRS7 + 177Lu-βS-hRS7? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call